Use of acanthopanax and radix cnidii for preparing antidepressant

Abstract

The application discloses a use of acanthopanax and radix xanthii for preparing an antidepressant. The application claims a use of acanthopanax and radix xanthii for preparing an antidepressant, wherein the antidepressant takes acanthopanax and radix xanthii as effective components, and the mass ratio of the acanthopanax to the radix xanthii is 2:1; and the application also claims an antidepressant composition, which is composed of acanthopanax and radix xanthii with a mass ratio of 2:1. It is found that acanthopanax and radix xanthii with a mass ratio of 2:1 have a significant synergistic effect on the antidepressant activity. Therefore, acanthopanax and radix xanthii with a mass ratio of 2:1 have a promising application prospect in the preparation of an antidepressant.

Description

Technical Field

[0001] This invention belongs to the field of medicine, specifically relating to the use of Acanthopanax senticosus and Cynanchum paniculatum in combination for the preparation of antidepressant drugs. Background Technology

[0002] Depression, also known as major depressive disorder (MDD), is a common mental disorder characterized by depressed mood, lack of interest and pleasure, accompanied by corresponding changes in thinking and behavior. It is one of the most prevalent mental illnesses worldwide. In Traditional Chinese Medicine (TCM), it is referred to as "Yu Zheng" or "emotional disorder," and can be diagnosed as emotional distress, physical weakness due to prolonged illness, overwork and excessive thinking damaging the heart and spleen, as well as improper diet, such as overeating or undereating, causing stomach upset and disharmony. TCM believes that Yu Zheng is mainly caused by the seven emotions of joy, anger, worry, pensiveness, grief, fear, and fright, resulting in restlessness and insomnia.

[0003] Western medicine treatment for depression, due to long-term use, may lead to adverse reactions such as dependence, toxicity, memory loss, organ dysfunction, and delayed clinical effects. In contrast, traditional Chinese medicine (TCM) has made significant progress in treating depression, slowing disease progression, improving the efficacy of Western medicine, and reducing side effects. TCM's syndrome differentiation and treatment have established classification standards, emphasizing the combination of deficiency and excess, and the use of compound prescriptions, demonstrating rapid antidepressant effects in clinical practice.

[0004] However, traditional Chinese medicine treatment for depression often involves large doses, leading to poor patient adherence in some cases. Therefore, identifying drugs with synergistic antidepressant effects is crucial for enhancing efficacy and reducing dosage. Summary of the Invention

[0005] The purpose of this invention is to provide the use of Acanthopanax senticosus and Cynanchum paniculatum in combination for the preparation of antidepressant drugs.

[0006] The above-mentioned objective of this invention is achieved through the following technical solution:

[0007] The combined use of Acanthopanax senticosus and Cynanchum paniculatum in the preparation of an antidepressant drug with Acanthopanax senticosus and Cynanchum paniculatum as active ingredients in a mass ratio of 2:1.

[0008] An antidepressant composition comprising Acanthopanax senticosus and Cynanchum paniculatum in a mass ratio of 2:1.

[0009] The above-mentioned antidepressant composition is used in the preparation of an antidepressant drug, wherein the antidepressant composition is used as the active ingredient and is formulated into a pharmaceutically acceptable dosage form using a pharmaceutically acceptable carrier or excipient.

[0010] Furthermore, the pharmaceutically acceptable carrier or excipient is a solid, liquid, or semi-solid carrier or excipient.

[0011] Furthermore, the pharmaceutically acceptable dosage forms include tablets, capsules, injections, microcapsules, and pellets.

[0012] Beneficial effects:

[0013] This invention reveals that Acanthopanax senticosus and Cynanchum paniculatum in a mass ratio of 2:1 exhibit a significant synergistic effect in antidepressant activity. Therefore, Acanthopanax senticosus and Cynanchum paniculatum in a mass ratio of 2:1 show promise for combined use in the preparation of antidepressant drugs. Detailed Implementation

[0014] The following describes the substantive content of the present invention in detail with reference to embodiments, but this does not limit the scope of protection of the present invention.

[0015] I. Experimental Materials

[0016] The experimental animals were SPF-grade male C57BL / 6J mice, purchased from Shanghai Xipu-Bikai Laboratory Animal Co., Ltd., weighing 20-22g and aged 7-8 weeks. Behavioral testing equipment was custom-made, and the software analysis was ANY-maze. Acanthopanax senticosus and Cynanchum paniculatum were purchased from the outpatient department of Nanjing University of Traditional Chinese Medicine. They were extracted with water at 55-65℃, concentrated, and the resulting liquid was used for later use.

[0017] II. Experimental Methods

[0018] 1. Animal grouping and administration

[0019] After acclimatization, mice were randomly divided into a control group, a Acanthopanax senticosus group, a Cynanchum paniculatum group, and a combined treatment group, with 10 mice in each group. Mice in the Acanthopanax senticosus group were administered Acanthopanax senticosus solution by gavage at a dose equivalent to 10g crude drug / kg; mice in the Cynanchum paniculatum group were administered Cynanchum paniculatum solution by gavage at a dose equivalent to 5g crude drug / kg; mice in the combined treatment group were administered Acanthopanax senticosus solution and Cynanchum paniculatum solution by gavage at a dose equivalent to 10g Acanthopanax senticosus solution / kg + 5g Cynanchum paniculatum solution / kg; and the control group was administered an equal volume of physiological saline by gavage. Tail suspension assays were performed 24 and 48 hours after administration.

[0020] 2. Mouse tail suspension test

[0021] The mouse's tail was securely taped to a suspension bar, with its head facing downwards, in an inverted, suspended position. The tape was strong enough to support the weight of the mouse being tested. The software recorded the cumulative immobility time over 6 minutes, and then recorded the immobility time over the last 4 minutes. Small movements involving only the forelimbs without hindlimb involvement were considered immobility; swaying due to inertia was also considered immobility.

[0022] 3. Statistical methods

[0023] Experimental results are expressed as mean ± s, and P < 0.05 indicates statistical significance.

[0024] The collaborative discrimination model is the Jin Zhengjun q-value method.

[0025] III. Experimental Results

[0026] The results of tail suspension tests after 24 hours are shown in Table 1, and the results after 48 hours are shown in Table 2. Compared with the control group, the immobility time of the suspended tails of mice in each drug-treated group was significantly shortened, and the shortening was more significant in the combined drug-treated group.

[0027] Table 1. Results of 24-hour tail suspension test

[0028] control group Combined drug administration group Acanthopanax senticosus group Xu Changqing Group Time the tail remains stationary (in seconds) 129.1±19.2 82.5±31.1 105.8±46.6 112.9±58.9 Inhibition rate / 36.1％ 18.0％ 12.5％ Kim Jong-kyun's q value / 1.28 / /

[0029] Table 248-hour tail suspension test results

[0030] control group Combined drug administration group Acanthopanax senticosus group Xu Changqing Group Time the tail remains stationary (in seconds) 153.8±38.0 86.6±27.8 112.1±29.8 116.2±23.9 Inhibition rate / 67.2％ 27.1％ 24.4％ Kim Jong-kyun's q value / 1.50 / /

[0031] The Jin Zhengjun q-value method is a commonly used method for evaluating the synergistic effect of drugs. The Jin Zhengjun q-value was calculated based on the inhibition rate of tail suspension immobility time to determine the effect of the combined use of Acanthopanax senticosus and Cynanchum paniculatum: q = Ea + b / (Ea + Eb - Ea × Eb), where Ea and Eb are the inhibition rates of Acanthopanax senticosus and Cynanchum paniculatum alone, respectively, and Ea + b is the inhibition rate of the combined drugs. In the formula, the numerator represents the "measured combined effect," the denominator is the "expected combined effect," and the q-value is the ratio of the two. q < 0.85 indicates an antagonistic effect, 0.85 ≤ q < 1.15 indicates an additive effect, and q ≥ 1.15 indicates a synergistic effect. The calculation results show that Acanthopanax senticosus and Cynanchum paniculatum in a mass ratio of 2:1 can synergistically inhibit tail suspension immobility time in mice, demonstrating that Acanthopanax senticosus and Cynanchum paniculatum in a mass ratio of 2:1 have a significant synergistic effect in antidepressant activity.

[0032] The purpose of the above embodiments is to specifically illustrate the substantive content of the present invention, but those skilled in the art should know that the scope of protection of the present invention should not be limited to the specific embodiments.

Claims

1. The use of an antidepressant composition in the preparation of an antidepressant drug, wherein the antidepressant composition is used as the active ingredient and is formulated into a pharmaceutically acceptable dosage form using a pharmaceutically acceptable carrier or excipient; wherein the antidepressant composition comprises Acanthopanax senticosus and Cynanchum paniculatum in a mass ratio of 2:

1.

2. The application according to claim 1, characterized in that: The pharmaceutically acceptable carriers or excipients are solid, liquid, or semi-solid carriers or excipients.

3. The application according to claim 1, characterized in that: Pharmaceutically acceptable dosage forms include tablets, capsules, injections, microcapsules, and pellets.